WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

(B) CDK1 and CDK2 bind to multiple cyclins (cyclin types A, B, D and E), whereas CDK4 and CDK6 only partner D-type cyclins. Thick lines represent the preferred pairing for each kinase. (C ...

This ensures that activation of Cdk2 and subsequent initiation of replication is co-ordinately regulated at, and localized to, replication origins. Figure 1: Recruitment of cyclin E/Cdk2/Xic1 and ...

p27 is a direct inhibitor of cyclin-dependent kinase 2 (cdk2), one of the cdks responsible for the activation of E2F1 transcription factors that promote DNA replication. [5] During periods of cell ...

Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...

This analysis segregated cell lines into distinct clusters demonstrating specific dependencies on various cyclin and CDK genes, revealing tumor types that are exceptionally dependent on CDK2 and ...

L.-H. Tsai, E. Harlow, M. Meyerson, "Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase," Nature, 353:174-7, 1991. Li-Huei Tsai (Massachusetts General ...

This analysis segregated cell lines into distinct clusters demonstrating specific dependencies on various cyclin and CDK genes, revealing tumor types that are exceptionally dependent on CDK2 and more ...